USPTO serial 90066400
PATIENTS CAN'T WAIT. NEITHER CAN WE.
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 25, 2024
- Examiner
- SCHLEGELMILCH, JONATHON A
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with PATIENTS CAN'T WAIT. NEITHER CAN WE.?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Princeton, NJ
PRINCETON, NJ
PRINCETON, NJ
Princeton, NJ
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
William M. Bryner
William M. Bryner KILPATRICK TOWNSEND & STOCKTON LLP1001 WEST FOURTH STREETWINSTON-SALEM, NC 27101United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Scientific research and development; pharmaceutical drug development and testing services; research and development of pharmaceuticals, medical devices, biotechnology, and biochemicals; medical and scientific research, namely, designing, organizing, conducting, monitoring, and managing clinical and non-clinical trials and studies on pharmaceuticals and medical devices for others; scientific consulting services for others in the field of clinical and non-clinical trials and studies on pharmaceuticals and medical devices; collection, calibration, analysis and reporting of medical and scientific research data in connection with clinical and non-clinical trials and studies on pharmaceuticals and medical devices; scientific laboratory services; scientific laboratory services, namely, formulating and bioprocessing pharmaceuticals; operating and maintaining a biorepository for medical and scientific research purposes; scientific research and analysis in the fields of bioinformatics, biomarkers, genomics, proteomics, genotyping, and genetic profiling; custom design and development of chemical reagents and biochemical assays; medical laboratory services in the field of pathology; computer hardware and software design; design and development of software for use in conducting biological research in non-clinical pharmaceutical and medical device and development studies; providing online computer databases in the fields of research and development of pharmaceuticals, medical devices, biotechnology, and biochemicals; data mining; providing a website featuring technology enabling users to remotely track, monitor, analyze, and generate reports with information and statistics from clinical and non-clinical trials and studies on pharmaceuticals and medical devices; scientific research and analysis in the field of pharmacology; advisory services in the field of pharmaceutical drug development, namely, selecting biological research models for use in testing drugs; advisory services in the field of pharmaceutical drug development, namely, selecting biomarkers for use in testing drugs; lead candidate drug optimization services, namely, scientific research in the field of identifying compounds for drug development; providing medical and scientific information in the fields of biochemistry, pharmaceuticals and clinical trials; acting as an application service provider featuring software for use in database and record management in the fields of medical testing, testing for forensic purposes, testing for quality control purposes, genetic testing, clinical and analytical testing, disease, medical care, healthcare, pharmaceuticals, medical devices, biochemicals, and biotechnology; providing non-downloadable software through a web-based portal to collect, organize, and report medical information, medical records, and diagnostic testing records; providing a web-based portal in the fields of medical testing for scientific research purposes, testing for forensic research purposes, testing for quality control purposes, genetic testing for scientific research purposes, and medical and scientific research in the field of, disease, medical care, healthcare, pharmaceuticals, medical devices, biochemicals, and biotechnology; providing temporary use of online non-downloadable software for storing, retrieving, accessing, displaying, managing, analyzing, and reviewing information and data in the fields of medical testing, testing for forensic purposes, testing for quality control purposes, genetic testing, clinical and analytical testing, disease, medical care, healthcare, pharmaceuticals, medical devices, biochemicals, and biotechnology; electronic storage of data; consulting services in the fields of testing for drug, alcohol and DNA screening for forensic research purposes and testing for quality control purposes; providing an online computer database in the fields of testing for drug, alcohol and DNA screening for forensic research purposes and testing for quality control purposes; providing a website featuring information in the fields of testing for drug, alcohol and DNA screening for forensic research purposes and testing for quality control purposes; medical testing for quality control purposes | ACTIVE | — |
| 044 | Medical services in the fields of pathology, pharmacology, and immunology; medical and psychological counseling; medical testing for diagnostic, treatment, or screening purposes; medical testing for forensic purposes; genetic testing for medical purposes; medical testing for diagnostic and treatment purposes; consulting services in the fields of medical testing, testing for medical forensic purposes, genetic testing for medical purposes and relating to diagnostic, prophylactic and therapeutic information in the fields of disease, medical care and healthcare; medical consulting in the field of patient management and outcomes; providing an online computer database in the fields of medical testing, testing for medical forensic purposes, genetic testing for medical purposes and relating to diagnostic, prophylactic and therapeutic information in the fields of disease, medical care, and healthcare; providing an online computer database featuring medical information in the field of patient management and outcomes; providing a website featuring information in the fields of medical testing, testing for medical forensic purposes, genetic testing for medical purposes and relating to diagnostic, prophylactic and therapeutic information in the fields of disease, medical care, and healthcare; providing a website featuring medical information in the field of patient management and outcomes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Covance, Inc.
- Other trademarks owned by LABCORP DRUG DEVELOPMENT INC.
- Other trademarks owned by LABCORP DRUG DEVELOPMENT INC.
- Other trademarks owned by Covance, Inc.
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named PATIENTS CAN'T WAIT. NEITHER CAN WE.
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 25, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jun 25, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 23, 2024 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| May 23, 2024 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| May 16, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 22, 2024 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Feb 15, 2024 | IUAF | USE AMENDMENT FILED | — |
| Feb 15, 2024 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Aug 25, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 24, 2023 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Aug 15, 2023 | EXT5 | SOU EXTENSION 5 FILED | — |
| Aug 15, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 24, 2023 | NOAC | CORRECTED NOA E-MAILED | — |
| May 31, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 30, 2023 | EX4G | SOU EXTENSION 4 GRANTED | — |
| May 30, 2023 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Apr 25, 2023 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Mar 13, 2023 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Feb 16, 2023 | EXT4 | SOU EXTENSION 4 FILED | — |
| Feb 16, 2023 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Feb 16, 2023 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Feb 16, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 7, 2022 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Aug 17, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 15, 2022 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Aug 15, 2022 | EXT3 | SOU EXTENSION 3 FILED | — |
| Aug 15, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 18, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 16, 2022 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Feb 16, 2022 | EXT2 | SOU EXTENSION 2 FILED | — |
| Feb 16, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 18, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 16, 2021 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 16, 2021 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 16, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 16, 2021 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 22, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 22, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 2, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 17, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 6, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 19, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 25, 2020 | NWAP | NEW APPLICATION ENTERED | — |